Egis in the World
Egis’ products reach 100 countries around the world.
Egis ’products reach countries. Our portfolio consists of 653 products. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.
Learn moreOur activities incorporate all areas of the pharmaceutical value chain
Click here to learn moreInnovation is one of the pillars of our strategy. We devoted EUR 48 million to research and development in the 2022/2023 business year.
Click here to learn moreThe predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.
The selection process for the position of Egis Group’s Commercial Director has been closed. As a result, dr Csaba Pácz remains head of the Commercial Directorate.
Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.